Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
IPO Year:
Exchange: NASDAQ
Website: arrowheadpharma.com
Recent Analyst Ratings for Arrowhead Pharmaceuticals Inc.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2024 | $31.00 | Neutral | Goldman |
| 12/4/2023 | $29.00 | Buy | BofA Securities |
| 9/19/2023 | $33.00 | Neutral | Citigroup |
| 7/21/2023 | Outperform | TD Cowen | |
| 5/12/2023 | $40.00 | Outperform → Market Perform | SVB Securities |
| 4/26/2023 | $80.00 | Outperform | SMBC Nikko |
| 4/12/2023 | $21.00 → $35.00 | Market Perform → Outperform | SVB Securities |
| 3/21/2023 | $27.00 | Mkt Perform | Bernstein |
| 9/9/2022 | $41.00 | Equal-Weight | Morgan Stanley |
| 5/11/2022 | $71.00 → $60.00 | Neutral → Outperform | Robert W. Baird |
Arrowhead Pharmaceuticals Inc. Press Releases
Fastest customizable press release news feed in the world
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company's Board of Directors approved "inducement" grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest annually over four years. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient mo
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
- ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria - Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Selec
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies - Data highlight Arrowhead's leadership in the use of RNA interference to potentially treat Obesity Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides Amplifying Patient Voices: The Spotlight on FCS white paper shares real patient experiences, highlighting the challenges of managing this ultra-rare disease and the need for greater awareness Commitment to the FCS Community: On Rare Disease Day and beyond, Arrowhead remains dedicated to elevating patient voices and fostering community engagement. #ForFCS Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) marks Rare Disease Day with the expansion of the We'll Get Th
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM™) pla
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
- Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over 5 years. Arrowhe
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will
Arrowhead Pharmaceuticals Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman initiated coverage on Arrowhead with a new price target
Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00
BofA Securities initiated coverage on Arrowhead with a new price target
BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00
Citigroup initiated coverage on Arrowhead with a new price target
Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00
TD Cowen initiated coverage on Arrowhead
TD Cowen initiated coverage of Arrowhead with a rating of Outperform
Arrowhead downgraded by SVB Securities with a new price target
SVB Securities downgraded Arrowhead from Outperform to Market Perform and set a new price target of $40.00
SMBC Nikko initiated coverage on Arrowhead with a new price target
SMBC Nikko initiated coverage of Arrowhead with a rating of Outperform and set a new price target of $80.00
Arrowhead upgraded by SVB Securities with a new price target
SVB Securities upgraded Arrowhead from Market Perform to Outperform and set a new price target of $35.00 from $21.00 previously
Bernstein initiated coverage on Arrowhead with a new price target
Bernstein initiated coverage of Arrowhead with a rating of Mkt Perform and set a new price target of $27.00
Morgan Stanley initiated coverage on Arrowhead with a new price target
Morgan Stanley initiated coverage of Arrowhead with a rating of Equal-Weight and set a new price target of $41.00
Arrowhead upgraded by Robert W. Baird with a new price target
Robert W. Baird upgraded Arrowhead from Neutral to Outperform and set a new price target of $60.00 from $71.00 previously
Arrowhead Pharmaceuticals Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Arrowhead Pharmaceuticals Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Chief Executive Officer Anzalone Christopher Richard was granted 340,000 shares and sold $774,975 worth of shares (51,425 units at $15.07), increasing direct ownership by 8% to 4,062,377 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Chief Executive Officer Anzalone Christopher Richard sold $5,274,334 worth of shares (300,000 units at $17.58) and exercised 300,000 shares at a strike of $7.75 (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Chief Executive Officer Anzalone Christopher Richard was granted 9,550 shares, increasing direct ownership by 0.25% to 3,773,802 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Director Ingram Douglas S was granted 38,396 shares (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
New insider Ingram Douglas S claimed no ownership of stock in the company (SEC Form 3)
3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Director Olukotun Adeoye Y sold $20,139 worth of shares (959 units at $21.00), decreasing direct ownership by 3% to 35,781 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Chief Discovery/Trans Medicine Hamilton James C was granted 100,000 shares and sold $648,824 worth of shares (32,729 units at $19.82), increasing direct ownership by 33% to 272,122 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
COO and General Counsel O'Brien Patrick was granted 100,000 shares and sold $736,059 worth of shares (37,184 units at $19.80), increasing direct ownership by 14% to 527,201 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Chief Financial Officer Myszkowski Kenneth Allen was granted 100,000 shares and sold $893,095 worth of shares (45,167 units at $19.77), increasing direct ownership by 14% to 455,433 units (SEC Form 4)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Arrowhead Pharmaceuticals Inc. SEC Filings
Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SEC Form 424B7 filed by Arrowhead Pharmaceuticals Inc.
424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SEC Form SCHEDULE 13D filed by Arrowhead Pharmaceuticals Inc.
SCHEDULE 13D - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.
10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SEC Form SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.
SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form 424B7 filed by Arrowhead Pharmaceuticals Inc.
424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SEC Form 10-K filed by Arrowhead Pharmaceuticals Inc.
10-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.
10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
Arrowhead Pharmaceuticals Inc. Leadership Updates
Live Leadership Updates
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi
Turnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022. Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said, "Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines." "I've watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years," said Ms. Vakiener. "I am excited to join the Board now to help contribute to its next phase of growth as Arrowhead takes the
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “
Arrowhead Pharmaceuticals Inc. Financials
Live finance-specific insights
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
- Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. "During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "The company is now well positioned for
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI10095fd77113444788810d4774d5fae3. Once registered, you will
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
- Conference Call and Webcast Today, November 26, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions of patients in need. We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, mor
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
– Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD – Additionally, Arrowhead and Sarepta have entered into a discovery partnership pursuant to which Sarepta will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across skeletal muscle, cardiac, and CNS – Investigational treatments leverage Arrowhead's leading Targeted RNAi Molecule (TRiMTM) platform, capable of deep and durable target-gene knockdown – Upon closing, Arrowhead to receive $500 million in an upfront paymen
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years - Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales - Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform - Arrowhead to discuss this agreement during the company's 2024 fiscal year end results conference call today, November 26, 2024, at 4:30 p.m. ET Ar
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIc060a13ae8224934aac09d48abe7b2f6. Once registered, you will receive the
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
- Conference Call and Webcast Today, August 8, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead had a very productive quarter with several high-profile presentations at medical and scientific congresses, as well as publications in high impact journals. Our clinical results have been strong and are receiving significant attention," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "Across our diverse pipeline, we continue to make good progress in later-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BI3ff87234939a4106b58ec6d3e72eb33c. Once registered, you will receive the dial-in number and a
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
- Conference Call and Webcast Today, May 9, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: "Arrowhead has achieved significant progress across our broad pipeline of investigational RNAi-based medicines that leverage the proprietary TRiMTM platform and we continued to strengthen our focus on and investment in our late-stage cardiometabolic programs. As we approach completion of the PALISADE Phase 3 study of ploza
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIf9305354ec6b44e3b3e946792a393a5e. Once registered, you will receive the dial-in
Arrowhead Pharmaceuticals Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.
SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc. (Amendment)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SEC Form SC 13G/A filed
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)